BioSig Technologies Inc has announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock at a price to the public of $1.15 per share for proceeds of $3 million.
The company also said it has issued a cash warrant at $1.40, which if fully exercised will see the company receive another $3 million of cash proceeds.
BioSig noted that it intends to use the net proceeds from the offering for the continuation of full commercialization activities related to its PURE EP System.
READ: BioSig Technologies to raise $3M in equity financing with family investment office
A shelf registration statement on Form S-3 (Registration No. 333-251859) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective on January 12, 2021.
BioSig Technologies is a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The company's first product, the PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact the author at jon.hopkins@proactiveinvestors.com